Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	63.4	75.05	93.12	203.43	288.64	181.38
Short-Term Investments	234.34	179.82	368.21	136.25	133.89	165.69
Cash & Cash Equivalents	297.74	254.87	461.33	339.68	422.53	347.07
Cash Growth	-52.91%	-44.75%	35.81%	-19.61%	21.74%	-2.51%
Receivables	147.73	144.16	165.5	148.93	140.88	87.33
Inventory	75.08	77.41	91.54	85.96	48.33	26.63
Other Current Assets	23.77	16.68	15.78	27.02	18.68	11.61
Total Current Assets	544.32	493.11	734.15	601.59	630.42	472.64
Property, Plant & Equipment	12.97	13.53	15.17	16.96	37.82	17.07
Long-Term Investments	11.66	16.62	93.9	119.17	350.36	591.77
Goodwill and Intangibles	696.77	716.91	819.48	902.21	442.25	24.84
Other Long-Term Assets	38.37	37.51	39.81	49.23	43.25	53.96
Total Long-Term Assets	759.77	784.56	968.36	1,088	873.69	687.64
Total Assets	1,304	1,278	1,703	1,689	1,504	1,160
Accounts Payable	86.4	79.57	96.34	117.68	78.93	49.71
Current Debt	0	0	401.97	0	0	0
Other Current Liabilities	228.15	210.63	189.65	197.7	166.17	110.87
Total Current Liabilities	314.55	290.2	687.96	315.38	245.11	160.59
Long-Term Debt	32.99	33.2	36	420.55	390.33	375.61
Other Long-Term Liabilities	27.38	32.77	92.35	137.37	123.81	28.66
Total Long-Term Liabilities	60.37	65.96	128.35	557.92	514.14	404.27
Total Liabilities	374.92	356.16	816.3	873.3	759.24	564.85
Total Debt	32.99	33.2	437.97	420.55	390.33	375.61
Debt Growth	-93.62%	-92.42%	4.14%	7.74%	3.92%	14.01%
Retained Earnings	482.69	482.56	481.25	379.92	326.5	199.55
Comprehensive Income	-0.53	-0.59	-3.21	1.54	8.98	7.42
Shareholders' Equity	929.17	921.52	886.2	815.85	744.86	595.43
Net Cash / Debt	264.74	221.68	23.37	-80.87	32.2	-28.54
Net Cash / Debt Growth	130.31%	848.64%	-	-	-	-
Net Cash Per Share	4.76	3.99	0.38	-1.49	0.60	-0.53
Working Capital	229.77	202.92	46.19	286.21	385.31	312.06
Book Value Per Share	16.95	16.90	16.51	15.37	14.16	11.36

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).